The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
Open Access
- 21 March 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (3) , 397
Abstract
Triple-negative breast cancers are particularly aggressive. In vitro cultures are one of the major pathways for developing anticancer strategies. The effectiveness and reproducibility of the drug screenings depend largely on the homogeneity of culture media. In order to optimize the predictive responses of triple-negative breast cancer 3D cell culture models, these works were focused on the development of SUM1315 and MDA-MB-231 cell lines in OptiPASS medium, a new serum-free formulation (BIOPASS). In monolayer cell culture, OptiPASS medium was more suitable for MDA-MB-231 than SUM1315 cell line but maintained cell phenotype and allowed sufficient proliferation. For spheroids produced in OptiPASS, the size monitoring showed a 1.3 and 1.5-fold increase for MDA-MB-231 and SUM1315 cell lines, respectively and viability/mortality profiles were maintained. Spheroids drug sensitivity thresholds were also improved allowing quicker high throughput drug screenings. These results showed the suitability of OptiPASS for 2D and 3D cell cultures of these two triple-negative breast cancer cell lines, with reproducibility of spheroid formation superior to 98%. This opens the way to the common use of this synthetic medium in future preclinical breast cancer research studies.Keywords
This publication has 33 references indexed in Scilit:
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Vimentin in cancer and its potential as a molecular target for cancer therapyCellular and Molecular Life Sciences, 2011
- 3D Models of Epithelial-Mesenchymal Transition in Breast Cancer Metastasis: High-Throughput Screening Assay Development, Validation, and Pilot ScreenSLAS Discovery, 2011
- “Humanized” Stem Cell Culture Techniques: The Animal Serum ControversyStem Cells International, 2011
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- High-throughput 3D spheroid culture and drug testing using a 384 hanging drop arrayThe Analyst, 2010
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research, 2010
- Recent advances in three‐dimensional multicellular spheroid culture for biomedical researchBiotechnology Journal, 2008
- Changing medium and passaging cell linesNature Protocols, 2007